{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:50:45Z","timestamp":1791510645337,"version":"4.3.4"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:p>Multiple myeloma (MM) is the second most prevalent hematological malignancy and is distinguished by the aberrant proliferation of monoclonal plasma cells inside the bone marrow and production of M-protein. This condition frequently results in bone deterioration, acute kidney damage, anemia, and hypercalcemia. However, the clinical manifestations and accompanying symptoms of MM vary and may change as the condition evolves. Therefore, diagnosis of MM is difficult. At present, the confirmation of MM diagnosis necessitates the use of bone marrow biopsy, a procedure that is both invasive and challenging for assessing dynamic alterations in the disease. The integration of laboratory testing technologies with imaging technology has the potential to enhance the diagnostic effectiveness and provide a thorough evaluation of disease progression and prognosis in patients with MM. All the examination methods have advantages and disadvantages. Therefore, diagnosis is determined by the application of clinical characteristics, serological tests, and imaging investigations.<\/jats:p>","DOI":"10.1097\/md.0000000000036660","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:09:22Z","timestamp":1704816562000},"page":"e36660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["New diagnostic strategy for multiple myeloma: A review"],"prefix":"10.1097","volume":"102","author":[{"given":"Ligong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4190-8664","authenticated-orcid":false,"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review.","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/asheducation-2015.1.272","article-title":"Evolving diagnostic criteria for multiple myeloma.","volume":"2015","author":"Rajkumar","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4329\/wjr.v13.i7.223","article-title":"Imaging in multiple myeloma: computed tomography or magnetic resonance imaging?","volume":"13","author":"Tagliafico","year":"2021","journal-title":"World J Radiol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma.","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jama.2021.25306","article-title":"What is multiple myeloma?","volume":"327","author":"Silberstein","year":"2022","journal-title":"JAMA"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00109-015-1345-4","article-title":"Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.","volume":"94","author":"Shay","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3892\/etm.2021.10764","article-title":"Modern markers for evaluating bone disease in multiple myeloma (Review).","volume":"22","author":"Pop","year":"2021","journal-title":"Exp Ther Med"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"e2107883","DOI":"10.1002\/adma.202107883","article-title":"Cancer-cell-biomimetic nanoparticles for targeted therapy of multiple myeloma based on bone marrow homing.","volume":"34","author":"Qu","year":"2022","journal-title":"Adv Mater"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative gn with monoclonal immunoglobulin deposits.","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood.2021011285","article-title":"Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.","volume":"138","author":"Caulier","year":"2021","journal-title":"Blood"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy.","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/medicina58030417","article-title":"The key role of Hepcidin-25 in anemia in multiple myeloma patients with renal impairment.","volume":"58","author":"Banaszkiewicz","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000354835","article-title":"Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients.","volume":"131","author":"Tarkun","year":"2014","journal-title":"Acta Haematol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000355129","article-title":"Growth differentiation factor 15 in multiple myeloma: a microenvironment factor predictive of response to treatment?","volume":"131","author":"Corre","year":"2014","journal-title":"Acta Haematol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/jcm8111828","article-title":"New biomarkers of ferric management in multiple myeloma and kidney disease-associated anemia.","volume":"8","author":"Banaszkiewicz","year":"2019","journal-title":"J Clin Med"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/ph11040135","article-title":"Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases.","volume":"11","author":"Petzer","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"R21-20250503","first-page":"1767","article-title":"Hepcidin-minireview.","volume":"7","author":"Palaneeswari","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"946","DOI":"10.5966\/sctm.2013-0055","article-title":"Concise review: growth differentiation factor 15 in pathology: a clinical role?","volume":"2","author":"Corre","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1532\/LH96.05030","article-title":"Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.","volume":"12","author":"Katodritou","year":"2006","journal-title":"Lab Hematol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.3390\/ijms241310801","article-title":"Diagnostic and prognostic value of PACAP in multiple myeloma.","volume":"24","author":"T\u00f3th","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1309\/AJCP25IHYLEWCAHJ","article-title":"Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients.","volume":"140","author":"McTaggart","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ejh.13771","article-title":"Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.","volume":"109","author":"Krhovska","year":"2022","journal-title":"Eur J Haematol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0000000000000615","article-title":"The microenvironment in myeloma.","volume":"32","author":"Lomas","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"R29-20250503","first-page":"109","article-title":"Assessment of bone marrow biopsy and cytogenetic findings in patients with multiple myeloma.","volume":"39","author":"Seyhanli","year":"2022","journal-title":"Turk J Haematol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00277-020-03959-x","article-title":"Plasmablastic IgM multiple myeloma with hypocellular bone marrow.","volume":"99","author":"Arter","year":"2020","journal-title":"Ann Hematol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1055\/a-0864-2084","article-title":"Imaging of multiple myeloma.","volume":"191","author":"Kosmala","year":"2019","journal-title":"Rofo"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: how? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma.","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br J Haematol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5312\/wjo.v5.i3.272","article-title":"Imaging of multiple myeloma: current concepts.","volume":"5","author":"Derlin","year":"2014","journal-title":"World J Orthop"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12288-010-0033-3","article-title":"Clinical features of bone complications and prognostic value of bone lesions detected by X-ray Skeletal Survey in Previously Untreated Patients with Multiple Myeloma.","volume":"26","author":"Li","year":"2010","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2214\/AJR.20.23204","article-title":"Whole-body low-dose CT in multiple myeloma: diagnostic value of appendicular medullary patterns of attenuation.","volume":"216","author":"Koutoulidis","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1148\/radiol.2017170281","article-title":"Multiple myeloma and dual-energy CT: diagnostic accuracy of virtual noncalcium technique for detection of bone marrow infiltration of the spine and pelvis.","volume":"286","author":"Kosmala","year":"2018","journal-title":"Radiology"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"W324","DOI":"10.2214\/AJR.14.12613","article-title":"Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma.","volume":"204","author":"Thomas","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiol.220311","article-title":"Photon-counting detector CT with deep learning noise reduction to detect multiple myeloma.","volume":"306","author":"Baffour","year":"2023","journal-title":"Radiology"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(87)92383-X","article-title":"Magnetic resonance imaging of the spine in multiple myeloma.","volume":"2","author":"Ludwig","year":"1987","journal-title":"Lancet"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma.","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/diagnostics12092182","article-title":"Advanced imaging in multiple myeloma: new frontiers for MRI.","volume":"12","author":"Torkian","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.acra.2010.08.002","article-title":"Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study.","volume":"17","author":"Fenchel","year":"2010","journal-title":"Acad Radiol"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1259\/bjr\/52759767","article-title":"Assessing response of myeloma bone disease with diffusion-weighted MRI.","volume":"85","author":"Messiou","year":"2012","journal-title":"Br J Radiol"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1148\/radiol.2016160363","article-title":"Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma.","volume":"282","author":"Koutoulidis","year":"2017","journal-title":"Radiology"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"e0180562","DOI":"10.1371\/journal.pone.0180562","article-title":"Diagnostic utility of whole body Dixon MRI in multiple myeloma: a multi-reader study.","volume":"12","author":"Bray","year":"2017","journal-title":"PLoS One"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1148\/radiol.211388","article-title":"Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma.","volume":"304","author":"Koutoulidis","year":"2022","journal-title":"Radiology"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11547-020-01258-z","article-title":"Quantitative bone marrow magnetic resonance imaging through apparent diffusion coefficient and fat fraction in multiple myeloma patients.","volume":"126","author":"Berardo","year":"2021","journal-title":"Radiol Med"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.diii.2019.05.001","article-title":"Improved contrast for myeloma focal lesions with T2-weighted Dixon images compared to T1-weighted images.","volume":"100","author":"Danner","year":"2019","journal-title":"Diagn Interv Imaging"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"key":"R53-20250503","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","article-title":"Value of FDG PET in the assessment of patients with multiple myeloma.","volume":"184","author":"Bredella","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma.","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00330-019-06469-1","article-title":"MRI versus (18)F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance.","volume":"30","author":"Lecouvet","year":"2020","journal-title":"Eur Radiol"},{"issue":"Suppl 1","key":"R56-20250503","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00259-017-3730-4","article-title":"Therapy assessment in multiple myeloma with PET.","volume":"44","author":"Nanni","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.3390\/cancers12113155","article-title":"Whole-Body Functional MRI and PET\/MRI in Multiple Myeloma.","volume":"12","author":"Mul\u00e9","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:24:37Z","timestamp":1746318277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":59,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036660","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}